DeShields says there can be additional barriers blocking patients access, including prior authorization requirements, restrictive use criteria, and substantial out-of-pocket costs. Of these, he says, affordability remains the largest obstacle to successful implementation in everyday medical practice. What are Aetnas coverage requirements for Wegovy
Antioxidant and Cytoprotective Actions: MOTS-c enhances the expression of antioxidant and stress-response genes, reducing oxidative stress and protecting mitochondrial integrity
Mochis model focuses on safe titration, active monitoring, and guidance to keep therapy sustainable
The treatment involves weekly dose escalation to a maintenance dose of up to 2.4 mg
This may manifest as redness, swelling, or soreness
Brendan Camp is a double board-certified dermatologist in dermatology and dermatopathology at MDCS Dermatology: Medical Dermatology & Cosmetic Surgery